The present invention relates to vacuum assisted wound treatment systems and methods, and more particularly to vacuum assisted wound treatment systems and methods that utilize a means for identifying infection through the use of optical analysis.
Vacuum induced healing of open wounds has recently been popularized by Kinetic Concepts, Inc. of San Antonio, Tex., by its commercially available V.A.C.® product line. The vacuum induced healing process has been described in commonly assigned U.S. Pat. No. 4,969,880 issued on Nov. 13, 1990 to Zamierowski, as well as its continuations and continuations in part, U.S. Pat. No. 5,100,396, issued on Mar. 31, 1992, U.S. Pat. No. 5,261,893, issued Nov. 16, 1993, and U.S. Pat. No. 5,527,293, issued Jun. 18, 1996, the disclosures of which are incorporated herein by this reference. Further improvements and modifications of the vacuum induced healing process are also described in U.S. Pat. No. 6,071,267, issued on Jun. 6, 2000 to Zamierowski and U.S. Pat. Nos. 5,636,643 and 5,645,081 issued to Argenta et al. on Jun. 10, 1997 and Jul. 8, 1997 respectively, the disclosures of which are incorporated by reference as though fully set forth herein.
These patents, and others, addressed the problems associated with closure of many types of wounds, including large or infected wounds. Wound closure typically involves the migration of epithelial and subcutaneous tissue towards the center of the wound site. In many wounds however, this migration is slowed or non-existent due to the size of the wound, and the degree of infection. Such wounds have been commonly closed using sutures or staples, with varying results. Improved techniques, as those described in the above mentioned patents, involve applying a negative pressure to the wound over an area sufficient to promote migration of epithelial and subcutaneous tissue toward the wound. Such techniques have been met with extremely positive results, and are currently being marketed and utilized by a device known as V.A.C.® (Vacuum Assisted Closure™), manufactured by Kinetic Concepts, Incorporated, of San Antonio, Tex.
One difficulty associated with the use of the V.A.C.® device, is that no suitable means for detecting the presence or kind of infection present in the wound is available, without disturbing the airtight dressing covering the wound.
Substantial work has been performed relating to the detection of microorganisms, which include spectrometers, chromatographs, and other electronic sensors for detecting the presence of microorganisms. Exemplary U.S. patents known to applicant include Lewis, et al. U.S. Pat. No. 6,017,440 issued Jan. 25, 2000; Chutjian, et al. U.S. Pat. No. 6,188,067 issued Feb. 13, 2001; Hunter, et al. U.S. Pat. No. 5,811,255 issued Sep. 22, 1998; Overton, et al. U.S. Pat. No. 5,611,846 issued Mar. 18, 1997; and Yu U.S. Pat. No. 5,583,281 issued Dec. 10, 1996; the disclosures of which are incorporated by reference herein.
As is well known to those of ordinary skill in the art, closure of surface wounds involves the inward migration of epithelial and subcutaneous tissue adjacent the wound. This migration is ordinarily assisted through the inflammatory process, whereby blood flow is increased and various functional cell types are activated. Through the inflammatory process, blood flow through damaged or broken vessels is stopped by capillary level occlusion; thereafter, cleanup and rebuilding operations may begin. Unfortunately, this process is hampered when a wound is large or has become infected. In such wounds, a zone of stasis (i.e. an area in which localized swelling of tissue restricts the flow of blood to the tissues) forms near the surface of the wound.
Without sufficient blood flow, the epithelial and subcutaneous tissues surrounding the wound not only receive diminished oxygen and nutrients, but also are also less able to successfully fight bacterial infection and thus are less able to naturally close the wound. Until the advent of vacuum induced therapy, such difficult wounds were addressed only through the use of sutures or staples. Although still widely practiced and sometimes effective, such mechanical closure techniques suffer a major disadvantage in that they produce tension on the skin tissue adjacent the wound. In particular, the tensile force required in order to achieve closure using sutures or staples may cause very high localized stresses at the suture or staple insertion point. These stresses commonly result in the rupture of the tissue at the insertion points, which can eventually cause wound dehiscence and additional tissue loss.
Additionally, some wounds harden and inflame to such a degree due to infection that closure by stapling or suturing is not feasible. Wounds not reparable by suturing or stapling generally require prolonged hospitalization, with its attendant high cost, and major surgical procedures, such as grafts of surrounding tissues. Examples of wounds not readily treatable with staples or suturing include large, deep, open wounds; decubitus ulcers; ulcers resulting from chronic osteomyelitis; and partial thickness burns that subsequently develop into full thickness burns.
As a result of these and other shortcomings of mechanical closure devices, methods and apparatus for draining wounds by applying continuous negative pressures have been developed. When applied over a sufficient area of the wound, such negative pressures have been found to promote the migration toward the wound of epithelial and subcutaneous tissues. In practice, the application to a wound of negative gauge pressure, commercialized by Assignee or its parent under the designation “Vacuum Assisted Closure” (or “V.A.C.®”) therapy, typically involves the mechanical-like contraction of the wound with simultaneous removal of excess fluid. In this manner, V.A.C.® therapy augments the body's natural inflammatory process while alleviating many of the known intrinsic side effects, such as the production of edema caused by increased blood flow absent the necessary vascular structure for proper venous return.
While V.A.C.® therapy has been highly successful in the promotion of wound closure, healing many wounds previously thought untreatable, some difficulty remains. Because the very nature of V.A.C.® therapy dictates an atmospherically sealed wound site, it is difficult to detect the presence or concentration of contaminant microorganisms, such as bacteria, that may be present in the wound site, without removing the wound dressing. It has heretofore been necessary to disturb the wound site, and thereby interrupt the therapy, in order to test for the presence or concentration of bacterial infection. Furthermore, any disturbance to the wound site may increase the possibility of infection to the wound site. Additionally, removal of the wound dressing may cause pain or discomfort to the patient.
Accordingly, a primary object of the present invention is to provide a vacuum assisted closure device that utilizes a means for detecting the presence of an infection present at a wound site during utilization of an airtight dressing, without disturbing the dressing at the wound site.
A further object of the present invention is to provide a means for identifying the nature or specific type of infection present at a wound site during the utilization of an airtight dressing, without disturbing the dressing at the wound site.
It is yet a further object of the present invention to provide a means for detecting the concentration of an infecting agent present at a wound site during utilization of an airtight dressing, without disturbing the dressing at the wound site.
In accordance with the foregoing objects, the present invention generally comprises a foam pad for insertion substantially into a wound site and a wound drape for sealing enclosure of the foam pad at the wound site. The foam pad, comprised of a foam having relatively few open cells in contact with the areas upon which cell growth is to be encouraged so as to avoid unwanted adhesions, but having sufficiently numerous open cells so that drainage and V.A.C.® therapy may continue unimpaired, is placed in fluid communication with a vacuum source for promotion of fluid drainage, as known in the art. Such communication may include a flexible tubing that is removably connected to the foam pad and the vacuum source. A connection adapter, sometimes referred to as an “elbow” adapter, an example of which is disclosed in
An infection detection means is connectable to the vacuum source, such that fluids being removed from the wound site will pass through the detection means during suction. The detection means is preferably positioned between the canister utilized to collect wound fluids in the traditional V.A.C.® and the vacuum source. However, it is to be understood that the detection means may be positioned anywhere along the line of suction from the wound site, so long as any filtration of the wound fluid occurs after passage of the fluid through the detection means.
The infection detection means is preferably comprised of an optical scanner that is capable of detecting changes in the frequency of light passing through the scanner. The frequency changes are identifiable to a particular bacterium, antigen, or other identifying source of infection. Alternative sensors include pH sensors for detecting changes in acidic concentrations of fluids being removed from the wound site during administration of negative pressure at the wound site.
Various types of detection devices may be utilized to detect the presence, concentration, and/or type of infection present in the wound site. Exemplary devices that may be utilized include those disclosed in the previously mentioned patents issued to Chutjan et al., Lewis et al., Hunter et al., and Overton et al.
Finally, many other features, objects and advantages of the present invention will be apparent to those of ordinary skill in the relevant arts, especially in light of the foregoing discussions and the following drawings and exemplary detailed description.
Although the scope of the present invention is much broader than any particular embodiment, a detailed description of the preferred embodiment follows together with illustrative figures, wherein like reference numerals refer to like components, and wherein:
Although those of ordinary skill in the art will readily recognize many alternative embodiments, especially in light of the illustrations provided herein, this detailed description is exemplary of the preferred embodiment of the present invention, the scope of which is limited only by the claims that may be drawn hereto.
Referring now to the figures, and to
As will be understood by those skilled in the art, alternate sensing devices may also be utilized for detecting the presence of microorganisms in the fluid being suctioned from the wound site by the vacuum pump 15. Examples of such alternate sensing devices include, but are not limited to miniature mass spectrometers, such as that described by Chutjan, et al. in U.S. Pat. No. 6,188,067 whose disclosure is incorporated herein by reference as though fully set forth. An alternate embodiment of the present invention may utilize sensor arrays similar to those described by Lewis, et al. in U.S. Pat. No. 6,017,440, whose disclosure is incorporated herein by reference as though fully set forth. Such a sensor array utilizes sensors comprised of regions of nonconducting organic material and regions of conducting organic material compositionally different than that of the nonconducting material.
The preferred sequential arrangement of the component parts of a V.A.C.® device utilizing the present invention is illustrated in
While the foregoing description is exemplary of the preferred embodiment of the present invention, those of ordinary skill in the relevant arts will recognize the many variations, alterations, modifications, substitutions and the like are readily possible, especially in light of this description and the accompanying drawings. In any case, because the scope of the present invention is much broader than any particular embodiment, the foregoing detailed description should not be considered as a limitation of the scope of the present invention, which is limited only by the claims that may be drawn hereto.
This application claims the benefit under 35 U.S.C. §119(e), of U.S. provisional patent application No. 60/273,587 filed Mar. 5, 2001.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vailancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielson | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4955391 | Parker et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5039491 | Saaski et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5237523 | Bonne et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | Debusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5437184 | Shillady | Aug 1995 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5583281 | Yu | Dec 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5611846 | Overton et al. | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5811255 | Hunter et al. | Sep 1998 | A |
5855570 | Scherson et al. | Jan 1999 | A |
6017440 | Lewis et al. | Jan 2000 | A |
6071267 | Zamierowski | Jun 2000 | A |
6120462 | Hibner et al. | Sep 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6188067 | Chutjian et al. | Feb 2001 | B1 |
6190858 | Persaud et al. | Feb 2001 | B1 |
6192753 | Czarnek | Feb 2001 | B1 |
6241747 | Ruff | Jun 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6398767 | Fleischmann | Jun 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstream et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
Number | Date | Country |
---|---|---|
550575 | Aug 1982 | AU |
745271 | Mar 2002 | AU |
755496 | Dec 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
295 04 378 | Sep 1995 | DE |
0117632 | Jan 1984 | EP |
0100148 | Feb 1984 | EP |
0161865 | Nov 1985 | EP |
0358 302 | Mar 1990 | EP |
1 018 967 | Aug 2004 | EP |
692578 | Jun 1953 | GB |
2 195 255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2333965 | Aug 1999 | GB |
2329127 | Aug 2000 | GB |
71559 | Apr 2002 | SG |
WO 8002182 | Oct 1980 | WO |
WO 8704626 | Aug 1987 | WO |
WO 9010424 | Sep 1990 | WO |
WO 9309727 | May 1993 | WO |
WO9420041 | Sep 1994 | WO |
WO 9605873 | Feb 1996 | WO |
WO 9718007 | May 1997 | WO |
WO 9913793 | Sep 1998 | WO |
WO 0059424 | Oct 2000 | WO |
Number | Date | Country | |
---|---|---|---|
20020143286 A1 | Oct 2002 | US |
Number | Date | Country | |
---|---|---|---|
60273587 | Mar 2001 | US |